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Background: People living with dementia in care homes frequently exhibit “behaviour that challenges”. Anti-psychotics
are used to treat such behaviour, but are associated with significant morbidity. This study researched the feasibility of
conducting a trial of a full clinical medication review for care home residents with behaviour that challenges, combined
with staff training. This paper focusses on the feasibility of measuring clinical outcomes and intervention costs.
Methods: People living with moderate to severe dementia, receiving psychotropics for behaviour that challenges, in care
homes were recruited for a medication review by a specialist pharmacist. Care home and primary care staff received
training on the management of challenging behaviour.
Data were collected at 8 weeks, and 3 and 6months. Measures were Neuropsychiatric Inventory-Nursing Home version
(NPI-NH), cognition (sMMSE), quality of life (EQ-5D-5 L/DEMQoL) and costs (Client Services Receipt Inventory).
Response rates, for clinical, quality of life and health economic measures, including the levels of resource-use
associated with the medication review and other non-intervention costs were calculated.
Results: Twenty-nine of 34 participants recruited received a medication review. It was feasible to measure the effects
of the complex intervention on the management of behaviour that challenges with the NPI-NH. There was valid NPI-
NH data at each time point (response rate = 100%). The sMMSE response rate was 18.2%. Levels of resource-use
associated with the medication review were estimated for all 29 participants who received a medication review. Good
response levels were achieved for other non-intervention costs (100% completion rate), and the EQ-5D-5 L and
DEMQoL (≥88% at each of the time points where data was collected).
Conclusions: It is feasible to measure the clinical and cost effectiveness of a complex intervention for behaviour that
challenges using the NPI-NH and quality of life measures.
Trial registration: ISRCTN58330068. Retrospectively registered, 15 October 2017.
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The number of people living with dementia is rapidly in-
creasing not just in the UK but internationally; in the UK
numbers are projected to increase by 209,600 new cases
per year [1]. The management of “behaviour that chal-
lenges” - the behavioural and psychological symptoms of
dementia (BPSD) - which includes symptoms such as agi-
tation, aggression, pacing, depression and hallucinations is
a key challenge in dementia care pathways [2] [3]. There
are significant costs associated with the management of
BPSD [4]. BPSD is also called challenging behaviour or be-
haviour that challenges and is defined as being ‘any behav-
iour considered antisocial within the care environment or
deemed dangerous to the person with dementia, their fel-
low residents, and staff’ [5].
Historically, antipsychotics have been used to treat
BPSD [2]. The Banerjee Report found that antipsychotics
were implicated in the death of 1800 people living with
dementia; they also potentially worsen quality of life [3].
Antipsychotics were frequently used as a first-line treat-
ment for behaviour that challenges that could be man-
aged by other approaches and two thirds of their use
may be inappropriate [3] [6]. Solely focussing on the
prescribing of antipsychotics may simply drive prescrib-
ing to other, equally risky, psychotropics (such as anti-
depressants and benzodiazepines), which also may
worsen quality of life [7] [8] [9]. Research should test in-
terventions to limit the use of all psychotropics [10] [11].
Prescribing within care homes in the UK is usually
undertaken by General Practitioners (albeit possibly fol-
lowing a secondary care review), with medication sup-
plied under the direction of a community pharmacist.
Pharmacist-led medication review in residential homes
may reduce prescribing of sedative and anticholinergic
drugs [12]. In the UK the need for more pharmacy
support in care homes has been identified [13]. Sec-
ondary care specialist dementia pharmacists may have
a vital role in ensuring the appropriate treatment of
BPSD [3] [14].
At least 300,000 people with dementia in the UK live
in a care home; these people have complex needs [15]
[16]. The need for training care home staff including
helping with coping strategies and job stress reduction
has been identified [17] [18]. A systematic review found
that staff training could improve the well-being of staff
working in dementia care, however the studies were
variable in quality [18]. The Well-being and Health for
People with Dementia (WHELD) study, which evaluated
the impact of antipsychotic review and a wellbeing
programme, concluded that a reduction in antipsychotic
use can be achieved but non-pharmacological interven-
tions are needed in parallel [19] [20].
This feasibility study involved a full clinical medication
review by a specialist dementia care pharmacistcombined with a health psychology informed behav-
ioural change training intervention for care staff. The
study aimed to provide key information on both study
processes and outcomes, so that we could understand
the challenges in evaluating the intervention [21]. This
paper focusses on the feasibility of measuring clinical
outcomes and intervention costs; recruitment and reten-
tion including implementation of the medication reviews
are reported elsewhere [22].
Aim
To determine whether it is feasible to measure the clin-
ical outcome and costs of a dual purpose pharmacy–
health psychology intervention incorporating medication
review and staff training to limit the prescription of psy-




An open label (non-blinded), mixed methods feasibility
study, set within the MRC framework for developing a
complex intervention was conducted [23]. The methods
have been described elsewhere [24]; the full protocol is
also available on www.aston.ac.uk/medrev. Briefly, the
intervention contained two key elements: a medication
review by a specialist dementia care pharmacist and
training for care staff.
Ethics
Ethical approval was received from the National Re-
search Ethics Service (15/EM/0314).
Setting
The study was conducted in five care homes in the West
Midlands UK, each with at least 40 residents including
people living with dementia from January 2015 until De-
cember 2017.
Study participants
Care homes in the West Midlands were eligible. Resi-
dents in care homes were eligible if they had a diagnosis
of dementia (e.g. on the GP dementia register) and were
receiving medication for behaviour that challenges [in-
cluding but not limited to medication in sections 4.1
(Hypnotics and Anxiolytics), 4.2 (Drugs used in psych-
oses and related disorders), 4.3 (anti-depressants) and
4.11 (Drugs used for Dementia) of the British National
Formulary edition 68].
Study procedures
Identification and recruitment of care homes
Care Homes meeting the inclusion criteria were identi-
fied from the Care Quality Commission (CQC) and
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Homes (ENRICH) initiative.
Recruitment of residents
People meeting the inclusion criteria, or their personal
consultee, were approached regarding participation. The
resident’s GP also had to consent to the medication re-
view. Written consent/assent was obtained from the par-
ticipant, or their personal consultee, as appropriate.
The target sample size was 45. This sample size
was based on the number required to estimate the
standard deviation for a subsequent sample size calcu-
lation [25] [26].
Intervention
A full clinical medication review was conducted by a
specialist dementia care pharmacist with the GP, the
person with dementia and their carer as per detailed
protocol [27]. The behavioural intervention consisted of
a 3-h training session for care staff promoting person-
centred care and brief training for primary care staff pri-
marily on the treatment of BPSD [22].
Outcome measures
Clinical Studies Officers (CSOs who undertake oper-
ational roles in research including data collection and
obtaining consent) from the local research network con-
ducted outcome assessments. The primary outcome
measure was the Neuropsychiatric Inventory-Nursing
Home version (NPI-NH) at 3 months after the medica-
tion was changed, or if the medication wasn’t changed
the date of the initial baseline. This was completed by a
Clinical Studies Officer questioning a member of care
home staff, who knew the resident well [28] [29]. Other
outcomes included quality of life (EQ-5D/DEMQoL)
[30] [31], cognition (Standardised Mini Mental State
Examination [sMMSE]) [32], service utilisation (modified
version of Client Services Receipt Inventory [CSRI]) [33]
and prescribed medication (including implementation of
the review).
Data were collected at 8 weeks, and at 3 and 6months
after the medication was changed/date of initial baseline.
Outcomes related to the feasibility included the feasibil-
ity of collecting clinical and cost-effectiveness data [e.g.
response rates for each of the measures (reported here)],
and recruitment and retention [22].
A qualitative evaluation exploring experiences and ex-
pectations of care home staff was conducted at the end
of the study, and will be reported separately. The chief
investigator (IM) also collected reflective comments
from care staff and members of the research team to
understand barriers and facilitators to participation and
implementation of the intervention to inform any future
trial, and if relevant these are reported below.Care home staff who attended the training completed
the Approaches to Dementia Questionnaire (pre-train-
ing, immediately and 3months post-training) [34] and
the Maslach Burnout Inventory – Human Services Sur-
vey (pre- and 3months post-training) [35]; (this will be
reported in a subsequent paper focussed on the Health
Psychology components of the intervention including
stakeholder accounts and results from the measures).Health economics
The health economics component sought to measure
the levels of participant resource use and quality of life,
to guide how costs and benefits could be measured in
any future definitive study. Reported costs are based on
the 2015/2016 financial year.Intervention costs
Care homes were provided with a three-hour training
session promoting person-centred care delivered by a
band 7 psychologist [£52 per working hour [36]], this
was provided twice in each care home. The average cost
per hour for those care home staff who received the
training was estimated to be £15.00 (including non-staff
costs).
Primary care staff, including GPs [£111 per working
hour [36]], practice nurses [£36 per working hour [36]]
and a pharmacist [£42 per working hour [36]] received a
briefer version of the training. Training delivery was
costed for a clinical psychologist principal [£62 per
working hour [36]] lasting 15 min when delivered by
phone and 30 min in person. No additional costs were
included for GP trainees when they joined a GP for face-
to-face training, for consumables, travel or preparation
time.
Levels of resource-use associated with the medication
review [including preparation e.g. accessing patient
notes, discussions (if applicable) with the patient, other
family members, and other staff in primary care/care
homes and time to make recommendations (including
associated paperwork)] were estimated by the pharma-
cist who delivered the intervention. Aforementioned unit
costs were then applied to all reported staff times, ex-
cluding travel, and then summed to estimate total inter-
vention costs. Travel times were not costed due to an
oversight related to the way the pharmacist was asked to
report the travel time on the form for each patient - the
form did not explicitly enable the pharmacist to report
whether the travel time related to more than one partici-
pant. Thus, it was unclear how many patients the re-
ported travel times should be apportioned across (this
could just be the one patient or all patients in the same
care home if the associated work was conducted on the
same day).
Table 1 Details of medication involved in medication reviews
(n = 21)







Co-prescribing of two hypnotics 1
Alendronic acid 1
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Research staff were asked to extract details of participant
use of other health care related services from care home
records and when required by discussion with care home
staff. Participants were no longer followed up for various
reasons including death and if the medication review
was not conducted [for full details see [22]].
Outcomes
Proxy completion of both the EQ-5D-5 L [37] and DEM-
QoL [38] was sought, where the caregiver, a member of
care home staff, was requested to respond “as if” they
were the person with dementia. In line with the NICE
Position statement [39] responses to the EQ-5D-5 L
were converted into utility scores [a scale where zero is
equal to death and one is full health [40]] using a map-
ping approach based on the three-level version [41]. Re-
sponses to the DEMQoL Proxy version were similarly
converted into utility scores [42]. Follow up was at base-
line, and at 3 and 6months post-implementation of the
medication review, in the absence of any of the afore-
mentioned exceptions. Also, at 8 and 16 weeks post-
baseline, if the medication review recommendation had
not been implemented then the baseline measures were
repeated (referred to as re-baselining).
In order to assess feasibility, response rates, for each of
the measures was estimated as a percentage of those for
whom an attempt was made to collect data (i.e. after ex-
cluding those who were not followed up for reasons ex-
plained above). For non-intervention costs we only
looked at the response at baseline as it was considered
that the availability of care home records should not vary
over time. Response rates for the EQ-5D-5 L and DEM-
QoL were estimated at baseline, 3 month and 6month
follow up points. Mean utility scores were also reported
at each of these time points, based on those with
complete data, though it is noted that these figures
should be treated with caution due to small numbers.
Results
Characteristics of the study population
Thirty-four care home residents were recruited to the
study, of whom 29 underwent a medication review
(85.3%). Medication reviews were not carried out for five
participants due to participant death (n = 2), primary
care engagement issues (n = 2), and the pharmacist being
unable to access primary care records (n = 1). The mean
age of the 29 study participants who received a medica-
tion review was 83.6 years (SD 9.3; range 66 to 100).
Eighteen participants were female (62.1%) and the
remaining 11 participants were male (37.9%). The major-
ity were White British in ethnicity (n = 24; 82.8%), with
four participants from non-white ethnic groups (13.8%)
(ethnicity data missing for one participant).Recommendations from medication reviews
A specialist dementia care pharmacist recommended
stopping or reviewing a medication in 21 of the 29 par-
ticipants who received a medication review (72.4%; see
Table 1). Fifteen of the 21 recommendations involved
antidepressants prescribing (71.4%; see Table 1).
Feasibility of clinical evaluation
The primary outcome measure was the difference in
NPI-NH total score between baseline (T0) and 3month
follow-up for participants whose medication had chan-
ged, compared to those whose medication did not
change. A reduction of 4 points is considered a clinically
important improvement/difference [28]. Table 2 summa-
rises mean NPI-NH total scores for participants.
For a number of participants there were several
baseline measurements due to the need to re-baseline
participants where recommendations had not been
implemented by the 8-week follow-up.
Overall, it appeared feasible to measure the clinical ef-
fectiveness of the intervention using the NPI-NH; data
were available for all participants who were still in the
study at each time point. For the group whose medica-
tion changed, there was an increase of 0.9 points in NPI
total score from baseline to 3 months (mean at T0 =
17.4, SD = 13.9; mean at 3 months = 18.3, SD = 12.3). For
those whose medication did not change, there was an in-
crease of 22.8 points (mean at T0 = 22.3, SD = 24.0;
mean at 3 months = 45.1, SD = 32.0; p = 0.03).
Cognitive impairment was measured using the
sMMSE. However, in practice, this measure did not
prove feasible, as the majority of participants could not
be rated using the measure at one or more time points
during the study. Taking all time points together, data
collection using the sMMSE was attempted on 88 occa-
sions, yet study participants could be rated using the
sMMSE in only 16 instances (18.2%). The Clinical Study
Officers took steps to address potential reasons for non-
completion. Some of these steps included having a quiet
private space, the presence of a helpful relative and
Table 2 Mean NPI total scores at each time point for participants whose medication changed vs. those where medication remained
the same
Baseline −2 Baseline −1 Baseline T0 8 week follow-up 3month follow-up 6month follow-up
Participants with a medication change
Number of participants n = 5 n = 11 n = 12 n = 11 n = 10 n = 5
Mean score (SD) 34.8 (30.5) 18.4 (19.7) 17.4 (13.9) 23.6 (22.6) 18.3 (12.3) 10.4 (8.4)
Range 10 to 70 0 to 71 0 to 51 0 to 77 0 to 33 0 to 18
Participants with no medication change
Number of participants n = 0 n = 0 n = 17 n = 13 n = 7 n = 4
Mean score (SD) N/A N/A 22.3 (24.0) 23.5 (28.7) 45.1 (32.0) 56.3 (39.7)
Range N/A N/A 0 to 83 0 to 59 22 to 120 0 to 114
Note: T0 is the baseline common to all participants, who received the medication review. Baseline −1 and − 2 refer to any previous baselining
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ing” was evident. Clinical Study Officers reported that
attempts to administer the questionnaire in participants
who were unable to respond could be distressing for
participants and themselves.
Feasibility of health economic evaluation
Intervention costs
Trainer and care home staff costs for 142 staff were esti-
mated to be £1560 and £6390, respectively. Costs for train-
ing primary care staff were £217 for the trainer and £958
for those receiving the training. Total training costs were
thereby estimated to be £9125, or £268.38 per participant
when equally apportioned across the 34 recruited partici-
pants. The pharmacist who delivered the intervention esti-
mated the levels of resource-use associated with the
medication review for all (100%) of the 29 participants who
received a medication review. The mean pharmacist time
per participant was 140min; further costs included consult-
ing care home staff for 23 of these participants (mean
time = 7min) and nurses for three participants (mean
time = 3min), and pharmacist follow-up for seven partici-
pants (mean time = 4min). In total, the mean cost of the
staff time associated with the medication review and the
intervention (training plus medication review) was £104.41
and £372.80 respectively per participant.
However, there is potential for some of the above inter-
vention costs to be off-set by savings elsewhere. For ex-
ample, some GPs mentioned that the training intervention
increased the confidence of care home staff to manage
BPSD non-pharmacologically without the need for GP in-
volvement. One GP stated that following the study, calls
on the surgery had reduced by about one per week.
Other (non-intervention) costs
Levels of resource use for non-intervention costs (the
CSRI) were available at baseline for the 29 participants
who received a medication review; indicating 100% com-
pletion rates. For both the EQ-5D-5 L and DEMQoL,
baseline data was obtained for 27 of the 29 participants,who received a medication review (93.1% response rate).
At the 3 month follow up point 88.2% of those for whom
it was requested responded (15/17), compared to 100%
at the 6 month follow up point (9/9).
For both the EQ-5D-5 L and DEMQoL, 9 participants
had complete data at each of the baseline, 3 month and
6month follow up points. The mean scores for the EQ-
5D-5 L, for these 9 participants, tended to be lower than
for the DEMQoL [0.293 (range: − 0.095 to 1), 0.260
(− 0.358 to 1) and 0.280 (− 0.028 to 1) respectively,
compared to 0.615 (0.538 to 0.672), 0.661 (0.412 to
0.900) and 0.662 (0.412 to 0.900) respectively]. Informal
feedback from the Clinical Study Officers who collected
the data was that the EQ-5D-5 L was more straightfor-
ward to rate.
Discussion
A number of studies have investigated psychosocial in-
terventions in care homes for behaviour that challenges
[19] [43]. However, there is little research on the feasibil-
ity and effectiveness of medication review for care home
residents [44] [45]. One trial has investigated a PCT/
CCG-led medication review, but this did not have a spe-
cific focus on behaviour that challenges [46]. To the best
of our knowledge, MEDREV is the first study to investi-
gate the impact of a psychosocial intervention plus spe-
cialist medication review on behaviour that challenges.
Overall, the NPI-NH appeared to be a suitable tool to
assess the clinical effectiveness of the intervention.
This confirms other studies; the WHELD intervention
improved the total NPI-NH compared to Treatment as
Usual by a mean difference of 4.55 (Standard Error of
Mean [SEM] 1.28; 95% CI − 7.07,− 2.02; Cohen’s D 0.30)
[19]; a similar result to MEDREV. Only a single
measurement-instrument was used to assess neuro-
psychiatric symptoms in MEDREV, unlike some other
studies, which used both the NPI and the Cohen-
Mansfield Agitation Inventory [19] [47]. However, the
Cohen-Mansfield may lack sensitivity to assess the broad
range of neuropsychiatric symptoms [47].
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core outcome measures for interventions to prevent or
slow the progress of dementia for people living with
mild to moderate dementia which recommend the NPI
for measurement of neuropsychiatry symptoms [48].
Based on MEDREV and other studies, this recommenda-
tion could be extended to complex interventions to
manage behavioural symptoms, and for people with
moderate to severe dementia. If only a single
measurement-instrument was used to rate such symp-
toms, this would reduce participant burden and costs.
The sMMSE lacked utility in this study; due to the de-
gree of cognitive impairment it was only able to be rated
in less than 20% of instances. This was despite taking
steps to ameliorate the reasons for non-completion. The
WHELD project used the Clinical Dementia Rating, an
assessment of global deterioration as an outcome meas-
ure [19]; other studies have used both the sMMSE and
the Severe Impairment Battery (SIB) [49]. The consensus
guidance recommended the use of MMSE or the Alzhei-
mer’s Disease Assessment Scale-Cognitive Scale [48].
However, the guidelines focus on assessing interventions
such as cholinesterase inhibitors and disease modifying
agents for mild to moderate dementia.
The research burden would be further simplified if a
single tool was used to rate quality of life. Informal feed-
back from the Clinical Study Officers who collected the
data favoured EQ-5D-5 L; this is also the tool recom-
mended by NICE for health economic evaluations [50].
Other studies and the consensus guidance recommend
DEMQOL [19] [48]. Both measures had good comple-
tion rates, however a noteable difference was that the
DEMQOL scores tended to be higher, but cover a
smaller range. This suggests that there is potential for
different utility measures to give different results, as has
been found previously [51] [52].
The cost of the intervention was substantial at ap-
proximately £100 per medication review, and training
costs of £270 per participant; although this might be off-
set by savings including reduced GP workload. Further-
more, agitation – a key symptom of BPSD – is
associated with significant costs; one-point increase in
the NPI agitation score has been estimated to increase
costs by £1064 over 12 months [4]. A recent Cochrane
review found that the effect of interventions to optimise
prescribing for older people in care homes on costs was
mixed; three studies found a reduction in costs whereas
two studies found no effect [53]. It cost £8627 per home
involved to deliver the WHELD intervention [19].
In MEDREV, specialist dementia care pharmacist
found that over 72% of residents with dementia re-
cruited to the study were receiving unnecessary medica-
tion for BPSD (mainly anti-depressants). This may
reflect the effectiveness of earlier national efforts toreduce antipsychotic prescribing for this target popula-
tion, or the high level of performance of care homes in-
terested in the research question. The evidence-base for
anti-depressants is limited; the largest published study
found an absence of benefit and an increased risk of ad-
verse events, and concluded that the routine use of anti-
depressants in people with dementia should be
reconsidered [54].
Limitations
This was a feasibility study and only involved small
numbers in a single area of the UK. The mean scores in
particular in Table 2 should be treated with caution due
to these small numbers and because the scores were
based on different numbers at each time point. However,
partly because of the ethics committee approved amend-
ment on re-baselining, the outcome measures were rated
on a significant number of occasions adding further
weight to the feasibility findings regarding the use of
these measures. The primary outcome for the study was
the change in NPI-NH total score and the feasibility of
collecting data on this. We have not included data on
the NPI-NH sub-scales (agitation, apathy etc.) due to the
small number of cases, but doing so would be a priority
in any subsequent definitive trial of medication reviews
that includes data collection using the NPI-NH
instrument.
The protocol approved by the ethics committee stated
that GP approval was required to enter residents into
the study and for the medication review to be con-
ducted. Participants (n = 3), for whom this approval was
not obtained, were withdrawn from the study before
baseline data was collected. Following an amendment,
again approved by the ethics committee, if the GP did
not implement the recommendations from the review
(n = 6), residents were removed from the study and did
not form part of the intention to treat analysis. As with
any complex intervention, it was not clear the relative
impact on the outcomes of the different components, in
this case the medication review and staff training.
Additionally, staff caring for participants in the no
medication change group still received the training
intervention.
The majority of participants were white and the find-
ings on the feasibility of the outcome measures require
confirmation in other populations. The sMMSE is an
adaptation of the Mini Mental State Examination
(MMSE), which has commonly been reported to have
cultural and educational biases [55] [56]. However, even
in this predominantly white population, the sMMSE was
not able to be rated in the majority of instances.
The health resource use questionnaire asked about re-
source use in the previous 3 months. It was not clear
how this was completed when the re-baseline time
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there may be duplication or time gaps. This coupled
with the follow up exceptions means that it is difficult to
estimate a common cost time period. As such only com-
pletion at baseline is reported.
Policy implications
Care home research is a key NIHR priority and future
research should build on the current evidence base [45].
Furthermore, any interventions developed and the ap-
proach to developing interventions should be grounded
in the reality of undertaking research in the care home
setting [45]. Care homes are busy environments and staff
time is precious, therefore research should aim to place
the minimum burden on the home, staff and residents
[57]. Based on the findings from this feasibility study,
the assessment burden could and should be simplified,
as much as is practical. Reflective comments also identi-
fied that researchers particularly Clinical Study Officers,
who were collecting data, needed to be flexible and
adaptive to the care home environment. This flexibility
included collecting data at a time convenient for the
home, avoiding peak times such as meal times and medi-
cation rounds.
Future research
In similar future studies, the assessment burden should
be rationalised; only a single quality of life measure, per-
haps the EQ-5D-5 L, should be included. The sMMSE
did not provide any useful data. Like other studies on
behavioural symptoms, the NPI-NH appeared to be a
suitable tool to assess the impact of a specialist medica-
tion review targeting all psychotropics. Future research
on the appropriate treatment of BPSD should include
the usage of all psychotropics and not solely focus on
anti-psychotics.
Conclusion
It was feasible to measure the clinical effectiveness of a
complex intervention for behaviour that challenges in
people with moderate to severe dementia using the NPI-
NH, but not the sMMSE. It was also feasible to measure
the impact of the intervention on quality of life, and the
costs associated with the intervention and other non-
intervention costs. The intervention shows some prom-
ise in ensuring the appropriate use of all psychotropics,
but further research is required.
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